*A practical framework for evaluating focal liver lesions in HPB clinic.* --- ### Essential Takeaway The first step in evaluating a liver lesion is not naming the lesion — it is defining the **clinical context**: 1. Does the patient have **known extrahepatic malignancy**? 2. Does the patient have **cirrhosis or chronic liver disease**? 3. Is the lesion **solid, cystic, vascular, or indeterminate**? 4. Has it been characterized with the **right imaging study**? 5. Would biopsy change management? Most liver lesions can be diagnosed noninvasively with high-quality multiphase imaging. Biopsy should be selective. --- ### Initial Questions #### 1. Is there known cancer? Known primary malignancy changes the differential. Common metastatic patterns: | Primary Cancer | Common Liver Lesion Concern | |---|---| | Colorectal cancer | Colorectal liver metastases | | Pancreatic cancer | Metastases | | NET | Hypervascular liver metastases | | Breast cancer | Metastases | | Melanoma | Metastases | | Gastric / esophageal cancer | Metastases | A new liver lesion in a patient with known cancer is not automatically metastatic, but it must be treated as suspicious until characterized. --- #### 2. Is there cirrhosis or chronic liver disease? In cirrhosis, the key diagnosis is **HCC**. Use LI-RADS terminology when appropriate. LI-RADS is designed for patients at risk for HCC and standardizes interpretation of CT/MRI liver lesions. :contentReference[oaicite:0]{index=0} Classic HCC imaging features include: - Arterial phase hyperenhancement - Portal venous or delayed washout - Capsule appearance - Threshold growth In the correct clinical context, HCC can often be diagnosed radiographically without biopsy. --- #### 3. Is the lesion solid or cystic? This is one of the most useful first branch points. | Lesion Type | Common Differential | |---|---| | Simple cystic | Simple cyst, biliary cyst, polycystic liver disease | | Complex cystic | Abscess, biliary cystadenoma/cystadenocarcinoma, necrotic metastasis | | Solid hypovascular | Metastasis, cholangiocarcinoma, atypical HCC | | Solid hypervascular | FNH, adenoma, HCC, NET metastasis | | Vascular | Hemangioma, AV shunt, vascular malformation | --- ### Preferred Imaging #### Best Next Test For most indeterminate liver lesions: > **MRI liver with multiphase contrast** is the best characterization study. MRI is particularly helpful for differentiating hemangioma, FNH, adenoma, HCC, cholangiocarcinoma, and metastases. ACR guidance emphasizes accurate characterization of incidental liver lesions because benign lesions are common, even in patients with known malignancy. :contentReference[oaicite:2]{index=2} --- ### Contrast Choice | Clinical Scenario | Preferred Study | |---|---| | Suspected colorectal liver metastases | MRI liver with hepatobiliary contrast | | Indeterminate liver lesion | MRI liver with hepatobiliary or extracellular contrast | | Cirrhosis / suspected HCC | Multiphase CT or MRI liver | | Suspected cholangiocarcinoma | MRI/MRCP or multiphase CT | | Pancreatic cancer staging | Pancreas protocol CT ± liver MRI | | NET metastases | Multiphase CT/MRI ± DOTATATE PET | | Cystic biliary lesion | MRI/MRCP | --- ### Common Benign Lesions #### Hemangioma Typical features: - Peripheral nodular discontinuous enhancement - Progressive centripetal fill-in - Very T2 bright on MRI Usually requires no treatment if confidently diagnosed. --- #### Focal Nodular Hyperplasia Typical features: - Arterial hyperenhancement - Central scar in some cases - Retains hepatobiliary contrast on delayed phase FNH is benign and generally does not require resection. --- #### Hepatic Adenoma Important because of: - Hemorrhage risk - Malignant transformation risk - Association with estrogen exposure, anabolic steroids, obesity/metabolic syndrome Management depends on size, sex, subtype, symptoms, growth, and imaging features. General principle: - Stop hormonal drivers if possible - Observe small, stable lesions - Consider resection for large, growing, symptomatic, β-catenin–activated, or male-associated adenomas EASL benign liver tumor guidance focuses on hemangioma, FNH, and hepatic adenoma as the major benign solid lesions requiring structured management. --- ### Malignant Lesions #### Colorectal Liver Metastases Key questions: - Number and distribution of lesions - Bilobar disease - Future liver remnant - Vascular/biliary involvement - Extrahepatic disease - Response to chemotherapy - Tumor biology Resectability is based on whether all disease can be cleared while leaving an adequate functional liver remnant. --- #### HCC Key questions: - Cirrhosis severity - Portal hypertension - Child-Pugh / MELD - Tumor size and number - Vascular invasion - Transplant eligibility - Resection vs ablation vs transplant vs locoregional/systemic therapy In cirrhosis, treatment is driven by both **tumor stage** and **liver function**. --- #### Intrahepatic Cholangiocarcinoma Key questions: - Mass-forming vs infiltrative pattern - Multifocal disease - Vascular/biliary involvement - Nodal disease - Future liver remnant - Need for staging laparoscopy - Role of systemic therapy Biopsy is often appropriate if neoadjuvant therapy or systemic therapy is being considered. --- #### NET Liver Metastases Key questions: - Functional vs nonfunctional tumor - Grade / Ki-67 - Liver tumor burden - Distribution of disease - Extrahepatic disease - Somatostatin receptor positivity - Cytoreduction feasibility NET liver metastases are often hypervascular and may be better seen on arterial phase imaging. --- ### When to Biopsy Biopsy is reasonable when: - Imaging is indeterminate - Diagnosis will change management - Systemic therapy requires tissue confirmation - There is no known primary cancer - Lesion does not fit expected imaging pattern - Molecular testing is needed Avoid biopsy when: - Imaging is diagnostic for benign disease - Imaging is diagnostic for HCC in the correct at-risk patient - Biopsy result would not change management - There is concern for unnecessary tumor seeding or bleeding risk --- ### Practical Clinic Framework #### Step 1: Define the host - Normal liver - Cirrhotic liver - Chemotherapy-exposed liver - Steatotic liver - Known extrahepatic malignancy #### Step 2: Define the lesion - Cystic vs solid - Hypervascular vs hypovascular - Single vs multifocal - Growing vs stable - Symptomatic vs incidental #### Step 3: Get the right imaging - MRI liver protocol for characterization - Multiphase CT when surgical anatomy/staging is needed - MRCP for biliary/cystic lesions - DOTATATE PET for suspected NET - PET/CT selectively for staging #### Step 4: Decide whether tissue is needed Biopsy only if it will alter treatment. #### Step 5: Decide management pathway - Reassure / no follow-up - Surveillance imaging - Hepatology referral - HPB surgery evaluation - Medical oncology referral - Multidisciplinary tumor board --- ### Red Flags Features that should prompt escalation: - Lesion growth - Multifocal disease - Arterial enhancement with washout - Restricted diffusion - Capsular retraction - Biliary obstruction - Vascular invasion - New lesion in patient with known cancer - Lesion in cirrhotic liver - Complex cystic lesion with mural nodularity or septations --- ### “Numbers I Carry” | Scenario | Practical Benchmark | |---|---| | Small simple cyst | Usually benign; no intervention if classic | | Classic hemangioma | No treatment if asymptomatic and diagnostic | | FNH | Benign; usually observe | | Adenoma >5 cm | Higher concern for bleeding/malignant transformation | | Cirrhotic liver lesion with APHE + washout | HCC until proven otherwise | | Known CRC + new liver lesion | CRLM until characterized | | NET metastases | Often hypervascular; arterial phase matters | --- ### Practice Point The most common mistake is skipping directly to biopsy before obtaining the correct liver protocol imaging. The second most common mistake is treating all liver lesions the same. The differential changes completely depending on whether the patient has a normal liver, cirrhosis, or known extrahepatic malignancy.